FIGHT: A randomized, double-blind, placebo-controlled, phase II study of bemarituzumab (bema) combined with modified FOLFOX6 in 1L FGFR2b+advanced gastric/gastroesophageal junction adenocarcinoma (GC).


Catenacci D. V. T. , Kang Y., Saeed A., Yamaguchi K., Qin S., Lee K., ...More

JOURNAL OF CLINICAL ONCOLOGY, vol.39, no.15, 2021 (Journal Indexed in SCI) identifier

  • Publication Type: Article / Abstract
  • Volume: 39 Issue: 15
  • Publication Date: 2021
  • Doi Number: 10.1200/jco.2021.39.15_suppl.4010
  • Title of Journal : JOURNAL OF CLINICAL ONCOLOGY